Literature DB >> 8757326

Defective transcription of the IL-2 gene is associated with impaired expression of c-Fos, FosB, and JunB in anergic T helper 1 cells.

A Mondino1, C D Whaley, D R DeSilva, W Li, M K Jenkins, D L Mueller.   

Abstract

Anergic CD4+ Th cells do not produce IL-2 when challenged with Ag-pulsed accessory cells because of a transcriptional defect. In this work, we report that these anergic T cells are defective in their ability to up-regulate protein binding and transactivation at two critical IL-2 DNA enhancer elements: NF-AT (nuclear factor of activated T cells; a sequence that binds a heterotrimeric NFATp, Fos, and Jun protein complex) and Activator Protein-1 (AP-1) (that binds Fos and Jun heterodimers). Western blot analysis of nuclear extracts showed that the impaired DNA-protein interactions in anergic T cells were associated with poor expression of the inducible AP-1 family members c-Fos, FosB, and JunB. However, the reduced expression of these proteins was not the result of a global TCR/CD3-signaling defect because CD3 cross-linking induced an equivalent increase in intracellular-free calcium ions, as well as NFATp dephosphorylation, translocation to the nucleus, and DNA binding in both normal and anergic T cells. Thus, defective IL-2 gene transcription appears to be due, at least in part, to a selective block in the expression of the AP-1 Fos and Jun family members in anergic T cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8757326

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Clinorotation differentially inhibits T-lymphocyte transcription factor activation.

Authors:  Maureen A Morrow
Journal:  In Vitro Cell Dev Biol Anim       Date:  2006 May-Jun       Impact factor: 2.416

Review 2.  Molecular mechanisms for adaptive tolerance and other T cell anergy models.

Authors:  Seeyoung Choi; Ronald H Schwartz
Journal:  Semin Immunol       Date:  2007-04-02       Impact factor: 11.130

Review 3.  mTOR at the crossroads of T cell proliferation and tolerance.

Authors:  Anna Mondino; Daniel L Mueller
Journal:  Semin Immunol       Date:  2007-03-23       Impact factor: 11.130

4.  Identification of the genes specifically expressed in orally tolerized T cells.

Authors:  Takayasu Gotoh; Wataru Ise; Atsuko Nonaka; Shuichi Hamaguchi; Satoshi Hachimura; Shuichi Kaminogawa
Journal:  Cytotechnology       Date:  2003-11       Impact factor: 2.058

5.  Analysis of sirtuin 1 expression reveals a molecular explanation of IL-2-mediated reversal of T-cell tolerance.

Authors:  Beixue Gao; Qingfei Kong; Kyeorda Kemp; Yuan-Si Zhao; Deyu Fang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-04       Impact factor: 11.205

Review 6.  Type 1 diabetes pathogenesis and the role of inhibitory receptors in islet tolerance.

Authors:  Tijana Martinov; Brian T Fife
Journal:  Ann N Y Acad Sci       Date:  2019-04-26       Impact factor: 5.691

7.  Ran overexpression leads to diminished T cell responses and selectively modulates nuclear levels of c-Jun and c-Fos.

Authors:  Xiaoying Qiao; Diep Ngoc Thi Pham; Hongyu Luo; Jiangping Wu
Journal:  J Biol Chem       Date:  2009-12-22       Impact factor: 5.157

Review 8.  Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 9.  The class III histone deacetylase sirtuin 1 in immune suppression and its therapeutic potential in rheumatoid arthritis.

Authors:  Sinyi Kong; Pricilla Yeung; Deyu Fang
Journal:  J Genet Genomics       Date:  2013-04-12       Impact factor: 4.275

10.  Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients.

Authors:  Barbara Cassani; Massimiliano Mirolo; Federica Cattaneo; Ulrike Benninghoff; Michael Hershfield; Filippo Carlucci; Antonella Tabucchi; Claudio Bordignon; Maria Grazia Roncarolo; Alessandro Aiuti
Journal:  Blood       Date:  2008-01-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.